Table 3 Selected clinical trials related to pyroptosis and the corresponding target
From: Pyroptosis in health and disease: mechanisms, regulation and clinical perspective
Drug | Signal pathway | Mechanism | Disease | References |
|---|---|---|---|---|
Colchicine | NLRP3 | Inhibit NLRP3 inflammasome activation and ‘cytokine storm’ | COVID-19 | |
Zinc supplementation | NLRP3/caspase-1 | Inhibit NLRP3 and caspase-1 expression | Behçet’s disease | |
Butyrate and Inulin | TLR2/NLRP3/caspase-1 NF-κB1/NLRP3/caspase-1 | Upregulate miR-146a and miR-9 hence inhibiting TLR2 and NF-κB1 | Type 2 diabetes | |
Coenzyme Q10 | NLRP3/ IL-1β | Suppress the recruitment of macrophages by inhibiting NLRP3/ IL-1β pathway | Myocardial infarction | |
Apatinib and Melittin | caspase-1/GSDMD AIM2/caspase-3/GSDME | Apatinib and melittin improve caspase‐1–GSDMD and AIM2-caspase‐3–GSDME pyroptosis, respectively | Anaplastic thyroid cancer | |
CAR-T cell | Caspase-3/GSDME | Release perforin and GzmB to induce tumor cell caspase-3-GSDME pyroptosis | CD19+ relapsed or refractory B cell leukemia | |
Dapansutrile | NLRP3/IL-6, IL-1β | Inhibit NLRP3 inflammasome thus hindering the cleavage of IL-6 and IL-1β | Gout |
